Generate Biomedicines Inc... (GENB)
주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.
Generate Biomedicines Inc.(GENB) 주가, 분석 및 데이터
데이터 없음
GENB 소개
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an ...
전체 기업 정보재무 실적
2025년 Generate Biomedicines의 매출은 31.89M로, 전년 20.46M 대비 55.89% 증가했습니다. 순이익은 -203.15M로, 16.91% 증가했습니다.
재무제표어닝 서프라이즈
- 매출 $6.31M 예상치 하회 $0, 및 Infinity% 전년 대비 성장.
- EPS -0.52 예상치 하회 -0.02, 및 -Infinity% 전년 대비 감소.
3주 전 · The Wall Street Journal
Jersey Mike’s Is the Latest Stock Slide in Trading Debuts This YearJersey Mike’s Subs, with its 5.96% stock-price decline Thursday, is hardly alone in having a first-day share slide. This year, shares for hedge fund Pershing Square, nuclear fuel company Standard Nucl...
